Abstract | INTRODUCTION: Cardiovascular (CV) diseases are the leading cause of death and disability in the developed countries. Lipid-lowering therapy is a cornerstone of the CV risk modification strategy. The first line treatment for hyperlipidemia is statins, which decrease low-density lipoprotein cholesterol ( LDL-C) by 30-50% and proportionally reduce the CV events. However, they are not always enough to achieve LDL-C goals in many patients, and some patients are statin intolerant. For this reason, new powerful injectable lipid-lowering drugs have been developed. AREAS COVERED: EXPERT OPINION:
|
Authors | Larysa Strilchuk, Federica Fogacci, Arrigo Fg Cicero |
Journal | Expert opinion on drug safety
(Expert Opin Drug Saf)
Vol. 18
Issue 7
Pg. 611-621
(07 2019)
ISSN: 1744-764X [Electronic] England |
PMID | 31100030
(Publication Type: Journal Article, Review)
|
Chemical References |
- Cholesterol, LDL
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hypolipidemic Agents
|
Topics |
- Animals
- Cardiovascular Diseases
(etiology, prevention & control)
- Cholesterol, LDL
(blood)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(administration & dosage, adverse effects)
- Hyperlipidemias
(complications, drug therapy)
- Hypolipidemic Agents
(administration & dosage, adverse effects)
- Injections
- Risk Factors
|